4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 101 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 1.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,218,405 | -32.1% | 1,902,467 | -3.6% | 0.00% | 0.0% |
| Q2 2023 | $35,653,952 | +34.2% | 1,973,102 | +27.6% | 0.00% | 0.0% |
| Q1 2023 | $26,573,745 | -6.0% | 1,545,884 | +21.5% | 0.00% | 0.0% |
| Q4 2022 | $28,255,785 | +166.1% | 1,272,210 | -3.6% | 0.00% | – |
| Q3 2022 | $10,617,000 | +15.1% | 1,320,362 | -0.1% | 0.00% | – |
| Q2 2022 | $9,228,000 | -52.7% | 1,322,149 | +2.4% | 0.00% | – |
| Q1 2022 | $19,519,000 | -30.7% | 1,290,941 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $28,152,000 | +10.3% | 1,283,083 | +35.6% | 0.00% | 0.0% |
| Q3 2021 | $25,513,000 | +125.3% | 945,977 | +101.2% | 0.00% | – |
| Q2 2021 | $11,325,000 | -40.3% | 470,276 | +7.6% | 0.00% | -100.0% |
| Q1 2021 | $18,969,000 | +4481.9% | 437,262 | +4272.6% | 0.00% | – |
| Q4 2020 | $414,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |